DEXTENZA Experience in the Office
DEXTENZA Experience in the Office

Ambulatory Surgery Center (ASC), Hospital Outpatient Department (HOPD)

Video Courtesy of Dr. Dee Stephenson*

Video Courtesy of Dr. Mitchell Jackson*

Video Courtesy of Dr. Paul Singh*

Video Courtesy of Dr. Mitchell Jackson*

DEXTENZA is benzalkonium chloride (BAK)-free, and therefore, does not expose the ocular surface to preservatives.1,2

DEXTENZA is a resorbable, fluorescein-conjugated, hydrogel-based intracanalicular insert designed to deliver a tapered dose of dexamethasone for up to 30 days following insertion and has a documented safety profile. 1,3

DEXTENZA is inserted at the site of care by an eye care professional.1,3

*Paid consultant providing services to Ocular Therapeutix, Inc.

References: 1. DEXTENZA [package insert]. Bedford, MA: Ocular Therapeutix, Inc; 2021. 2. Pauly A, et al. Molecular Vision. 2011;17:745-755. 3. Sawhney AS, et al., Inventors; Incept, LLC, Assignee. Drug delivery through hydrogel plugs. US patent 8,409,606 B2. April 2, 2013.




DEXTENZA is contraindicated in patients with active corneal, conjunctival or canalicular infections, including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella; mycobacterial infections; fungal diseases of the eye, and dacryocystitis.


Intraocular Pressure Increase – Prolonged use of corticosteroids may result in glaucoma with damage to the optic nerve, defects in visual acuity and fields of vision. Steroids should be used with caution in the presence of glaucoma. Intraocular pressure should be monitored during treatment.

Bacterial Infections – Corticosteroids may suppress the host response and thus increase the hazard for secondary ocular infections. In acute purulent conditions, steroids may mask infection and enhance existing infection.

Viral Infections – Use of ocular steroids may prolong the course and may exacerbate the severity of many viral infections of the eye (including herpes simplex).

Fungal Infections – Fungus invasion must be considered in any persistent corneal ulceration where a steroid has been used or is in use. Fungal culture should be taken when appropriate.

Delayed Healing – Use of steroids after cataract surgery may delay healing and increase the incidence of bleb formation.

Other Potential Corticosteroid Complications – The initial prescription and renewal of medication order of DEXTENZA should be made by a physician only after examination of the patient with the aid of magnification, such as slit lamp biomicroscopy, and, where appropriate, fluorescein staining. If signs and symptoms fail to improve after 2 days, the patient should be re-evaluated.


Ocular Inflammation and Pain Following Ophthalmic Surgery
The most common ocular adverse reactions that occurred in patients treated with DEXTENZA were: anterior chamber inflammation including iritis and iridocyclitis (10%), intraocular pressure increased (6%), visual acuity reduced (2%), cystoid macular edema (1%), corneal edema (1%), eye pain (1%), and conjunctival hyperemia (1%). The most common non-ocular adverse reaction was headache (1%).

Itching Associated with Allergic Conjunctivitis
The most common ocular adverse reactions that occurred in patients treated with DEXTENZA were: intraocular pressure increased (3%), lacrimation increased (1%), eye discharge (1%), and visual acuity reduced (1%). The most common non-ocular adverse reaction was headache (1%).


DEXTENZA is a corticosteroid indicated for:

  • The treatment of ocular inflammation and pain following
    ophthalmic surgery.
  • The treatment of ocular itching associated with allergic
Skip to content